Patents Assigned to Bioinfra Inc.
  • Patent number: 8435748
    Abstract: The present invention relates to a method for diagnosis and screening of cancer by measuring the expression of des-R prothrombin activation peptide fragment F2 (des-R F2) in serum, more precisely, des-R-prothrombin activation peptide fragment F2 which is the protein marker down-regulated specifically in liver cancer, breast cancer, and stomach cancer, and a method for diagnosis and screening of liver cancer, breast cancer, and stomach cancer by quantifying the protein marker. The protein marker of the present invention can be effectively used for diagnosis and screening of liver cancer, breast cancer and stomach cancer by comparing the expression of the said protein marker in a normal subject with that of a liver cancer, breast cancer, or stomach cancer patients.
    Type: Grant
    Filed: March 13, 2009
    Date of Patent: May 7, 2013
    Assignee: Bioinfra Inc.
    Inventors: Chul Woo Kim, Pil Je Park, Yong-Sung Shin, Kil Hyon Lee, Ho Sang Shin, Byoung-Kwon Kim
  • Patent number: 8399426
    Abstract: The present invention relates to adenine nucleotide translocator 2 (ANT2) siRNA (small interfering RNA) or ANT2 shRNA (short hairpin RNA) suppressing the expression of ANT2 gene expression and anticancer agent containing the same. Furthermore, the present invention relates to methods for treating breast cancers or stem cells of a breast cancer by treating the same with ANT2 siRNA or ANT2 shRNA. In addition, the invention provides a method for inhibiting metastasis of breast cancer cells with ANT2 siRNA or ANT2 shRNA.
    Type: Grant
    Filed: February 18, 2011
    Date of Patent: March 19, 2013
    Assignee: Bioinfra Inc.
    Inventors: Chul Woo Kim, Ji Young Jang
  • Publication number: 20110207798
    Abstract: The present invention relates to adenine nucleotide translocator 2 (ANT2) siRNA (small interfering RNA) or ANT2 shRNA (short hairpin RNA) suppressing the expression of ANT2 gene expression and anticancer agent containing the same. Furthermore, the present invention relates to methods for treating breast cancers or stem cells of a breast cancer by treating the same with ANT2 siRNA or ANT2 shRNA. In addition, the invention provides a method for inhibiting metastasis of breast cancer cells with ANT2 siRNA or ANT2 shRNA.
    Type: Application
    Filed: February 18, 2011
    Publication date: August 25, 2011
    Applicant: BIOINFRA INC.
    Inventors: Chul Woo KIM, Ji Young JANG
  • Publication number: 20110086404
    Abstract: The present invention relates to a method for diagnosis and screening of cancer by measuring the expression of des-R prothrombin activation peptide fragment F2 (des-R F2) in serum, more precisely, des-R-prothrombin activation peptide fragment F2 which is the protein marker down-regulated specifically in liver cancer, breast cancer, and stomach cancer, and a method for diagnosis and screening of liver cancer, breast cancer, and stomach cancer by quantifying the protein marker. The protein marker of the present invention can be effectively used for diagnosis and screening of liver cancer, breast cancer and stomach cancer by comparing the expression of the said protein marker in a normal subject with that of a liver cancer, breast cancer, or stomach cancer patients.
    Type: Application
    Filed: March 13, 2009
    Publication date: April 14, 2011
    Applicant: BIOINFRA INC.
    Inventors: Chul Woo Kim, Pil Je Park, Yong-Sung Shin, Kil Hyon Lee, Ho Sang Shin, Byoung-Kwon Kin
  • Patent number: 7892761
    Abstract: The present invention relates to protein markers for diagnosing stomach cancer and a diagnostic kit using the same, more precisely protein markers screened by two-dimensional gel electrophoresis and bioinformatics and a diagnostic kit using the same. The markers of the invention can be effectively used for diagnosing stomach cancer and evaluating the extent of progress of the cancer by confirming the expression levels of those marker proteins whose expressions differ in stomach cancer patients from in normal healthy people.
    Type: Grant
    Filed: December 28, 2006
    Date of Patent: February 22, 2011
    Assignee: Bioinfra Inc.
    Inventors: Chul Woo Kim, Syng-Yup Ohn, Mi Young Han, Yong-Sung Shin
  • Publication number: 20080286238
    Abstract: A recombinant adenovirus expressing a streptolysin O (SLO) protein comprising a SLO gene; a promoter operably linked to the SLO gene; a polyadenylation signal sequence; and an adenovirus genome lacking E1 gene effectively kills a cancer cell by expressing a pore-forming toxin, SLO protein, and, therefore, is useful for the suicide cancer gene therapy.
    Type: Application
    Filed: October 26, 2006
    Publication date: November 20, 2008
    Applicants: Bioinfra Inc.
    Inventors: Chul Woo Kim, Wan Seok Yang, Min Kyoung Kim